NCT02574455: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02574455 |
|---|---|
| Title | An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 7, 2017 |
| Completion date | March 30, 2020 |
| Required reporting date | March 30, 2021, midnight |
| Actual reporting date | March 11, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |